RUNX2 and osteosarcoma: Others have explored proteasome inhibitors in osteosarcoma and have proposed as potential mechanisms increased MAPK pathway activity and apoptosis40, decreased invasion and increased G2M cell cycle arrest41, and increased apopotosis through RUNX2 stabilization42.